CD274 and non-small cell lung carcinoma: Numerous studies have demonstrated that immunotherapy, especially with inhibitors of PD-1 or PDL1, has improved the prognosis of NSCLC patients and reformed therapeutic strategies for NSCLC [4, 7, 35].